Vasomune Therapeutics, Inc.

Vasomune Receives a US $6.4 Million PRMRP Grant from the US Department of Defense and up to $2.8 Million from NRC IRAP to Support the Development of AV-001 for the Treatment of Patients with Severe COVID-19 Disease and COVID-associated ARDS. https://lnkd.in/gNwiGnJy

Fascinating research and promising results for Vasomune's AV-001 to treat Vascular Dementia, "...the second most frequent subtype of dementia after Alzheimer’s disease, accounting for about 20% of dementia cases in North America." From the publication: AV-001 treatment alleviates neurological deficits and long-term memory impairment AV-001 treatment improves WM (white matter) integrity and promotes axonal/WM remodeling AV-001 significantly decreases the expression of cytokines in CSF (cerebrospinal fluid)

Vascular endothelial dysfunction is a key driver of so many devastating diseases. Congratulations to the team of Dr. Michael Chopp at Henry Ford Hospital, particularly Dr. Huanjia Gao, for a fascinating look at how AV-001 might be used in the treatment of vascular dementia. Thanks to Dr. Harold Kim for supporting this fruitful collaboration. https://lnkd.in/gsTUWyVA #Vasomune #dementia

It was our honour to host this opening #marsimpacthealth start-up pitch session, and introduce an amazing group of #entrepreneurs and new health #innovations from Vasomune Therapeutics, Inc., Ripple Therapeutics , QurCan Therapeutics Inc., NorthMiRs, Modulari-T Bio, Canurta Therapeutics and Intrepid Labs to the community.... Many thanks to MaRS Discovery District for the opportunity and to everyone who joined the session!

Join Dr. Brian Jahns for a presentation of Vasomune Therapeutics, Inc., MaRS Discovery District Impact Health Conference, June 12 and 13. https://lnkd.in/g-ZtCSy

Join Dr. Brian Jahns for a presentation of Vasomune Therapeutics, Inc., MaRS Discovery District Impact Health Conference, June 12 and 13. https://lnkd.in/g-ZtCSy

On Monday June 5 at 3pm PST I present the Vasomune Therapeutics story. Join me in Theater 3 for the story of how we achieved the ATS Late Breaker and Fast Track Designation, and what our vision is, for the future. https://lnkd.in/gBj3A9mu

Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001 Vasomune is delighted to announce that AV-001 has received Fast Track Designation from the FDA for the prevention or treatment of moderate-to-severe ARDS in patients hospitalized with viral and/or bacterial respiratory infections. We feel this is a great day for patients, and Vasomune is deeply indebted to our researchers, their patients, and to our supporters. https://lnkd.in/gwURKn2P Vasomune Therapeutics was created as a collaboration between Sunnybrook and TIAP - Toronto Innovation Acceleration Partners, and has advanced from bench to bedside with the support of Anges MG, Inc, Inc., United States Department of Defense CDMRP, National Research Council Canada / Conseil national de recherches Canada IRAP program, and Genome Canada. Vasomune is thankful for support and collaboration from MaRS Discovery District, Ontario Bioscience Innovation Organization (OBIO), BioBridges, Todd Strategy Group, BIOTECanada, and Biotechnology Innovation Organization

On May 21, 2024, Vasomune's Dr. Harold Kim will present Phase 1 safety, and pharmacokinetic and pharmacodynamic data for AV-001 as a late-breaking scientific poster at the American Thoracic Society Clinical and Scientific sessions. “Peer-reviewed presentation of our Phase 1 data is an important landmark in Vasomune and AnGes' development of AV-001” said Dr. Brian Jahns. https://lnkd.in/gYM4HPAk Clinical and Scientific Sessions Date: May 21, 2024 Presentation Time: 11:30 AM – 1:15 PM PT Session (C40): ARDS and Acute Respiratory Failure: Mechanism, Risk and Outcomes Poster: 14798 - A Randomized, Double‑Blind, Placebo‑Controlled Phase 1 Single and Multiple‑Dose Pharmacokinetic First‑In‑Human Study of AV‑001 in Healthy Subjects for the Treatment of Acute Respiratory Distress Syndrome A copy of the presentation materials can be accessed by visiting https://vasomune.com/ after the conclusion of the ATS Conference.

“The aim of AV-001, our first-in-class injectable Tie2 selective-receptor agonist, is to stabilize and normalize vascular dysfunction, blocking vascular leak,” said Dr. Harold Kim, Vice-President of Research and Scientific Affairs at Vasomune Therapeutics. “Our initial indication is ARDS resulting from infection, however AV-001 has the potential to be used in other diseases where vascular leak forms an underlying pathophysiology.” Vasomune Therapeutics was created as a collaboration between Sunnybrook and TIAP - Toronto Innovation Acceleration Partners, and has advanced from bench to bedside with the support of AnGes, Inc., United States Department of Defense, and National Research Council Canada / Conseil national de recherches Canada. Read about our journey in BioPharma Dealmakers on-line: https://lnkd.in/eGGsSaM9 #Vasomune